@article{oai:yachts.repo.nii.ac.jp:00000068,
 author = {前田,  邦彦 and 二宮,  ゆかり and 松田,  幹夫},
 journal = {山形保健医療研究 = Yamagata Journal of Health Sciences},
 month = {Jan},
 note = {論文(Article), Abstract：Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase type receptor glycoprotein, which is overexpressed for some patients with breast carcinoma (BC). HER2 status should be incorporated into a clinical decision concerning BC treatment along with other clinicopathologic factors, because it has emerged that HER2 overexpression is associated with not only effectiveness of the newly developed antibody-therapy using trastuzumab, which targets for HER2, but also clinical outcomes of BC patients and sensitivity to different types of chemotherapeutic agents. In order to evaluate actual situation of diagnosis and treatment for BC in Yamagata prefecture, we reviewed practice and procedure on BC treatment, especially examination and results on HER2 status, using our original questionnaire in the present study. Consequently, the following results were obtained: 1) Actual number of BC cases treated with surgery was markedly increased during last 8 years in Yamagata prefecture. 2) HER2 positive rate in this area was appropriate 10.6 %, which appeared to be lower than other areas. 3) Concerning distribution of HER2 status, there was somewhat a difference between each hospital. To establish more adequate circumstance for BC treatment, accurate examination on HER2 status and the construction of the appropriate quality control system should be required. Key words：HER2/neu, c-erbB-2, immunohistochemistry (IHC)，fluorescence in situhybridization (FISH)，trastuzumab (Hercepti)},
 pages = {61--69},
 title = {山形県の乳癌の病理学的特性 : HER2 (human epidermal growth factor receptor 2)の発現率に関する調査},
 volume = {13},
 year = {2010}
}